More DCAT Value Chain Insights

In-depth analysis of the critical issues impacting the full spectrum of the pharmaceutical manufacturing value chain.

Virtual pharmaceutical companies often have strong regulatory and clinical teams, but lack the resources needed to address the complexities of the complete product development and commercialization cycle. Partnering with a contract development and...

What have been the key developments in 2021 thus far in the CDMO market? Increasing participation by CDMOs in COVID-19 vaccine manufacturing and robust mergers and acquisition activity have marked the first half of 2021. What are the implications,...

Cell and gene therapies are a niche, but growing part of the bio/pharma industry. DCAT Value Chain Insights looks at key market activity: number of developers, commercial products, pipelines, and financing trends. Where does the industry stand,...

How are small molecules & biologics trending among new drug approvals and potential blockbuster drugs? Will biologics overtake small molecules as the leading modality, and if so, in what areas? DCAT Value Chain Insights takes the pulse of the...

Despite significant disruption and reprioritization of clinical trial activity during 2020 due to COVID-19, R&D activity levels remained at historically high levels, driven by new funding and strategic transactions, especially within oncology,...

The European Commission has updated the EU’s Industrial Strategy, which was first put forth in March 2020 with goals of realizing a green and digital economy while increasing the EU’s global competitiveness. The strategy involves improving...

The bio/pharma industry is based on batch manufacturing, so how is the adoption of continuous manufacturing for drug substances and drug products progressing? A pending ICH guideline clarifies technical and regulatory issues. And, views from the...

What has been the impact of COVID-19 on bio/pharmaceutical companies’ bottom line? For companies successfully bringing products for COVID-19 to fruition, 1Q 2021 results have been positive. What is expected for the rest of 2021? DCAT Value Chain...